Chronic oral amiodarone but not dronedarone therapy increases ventricular defibrillation threshold during acute myocardial ischemia in a closed-chest animal model

Journal of Cardiovascular Pharmacology
Philippe ChevalierBernard Bui-Xuan

Abstract

Dronedarone, a recently approved antiarrhythmic drug, has been shown to have fewer side effects than amiodarone, particularly with regard to thyroid and neurologic events. Since the effects of either drug on ventricular defibrillation threshold during ischemia are unknown, the aim of this study was to compare the effects of dronedarone and amiodarone on defibrillation efficacy during ischemia in a closed-chest animal model. Dronedarone (30 mg·kg·d) and amiodarone (20 mg·kg·d) were administered orally for 3 weeks to 19 and 21 pigs, respectively. A control group (no treatment) comprised 19 pigs. A 2-lead endovascular defibrillation system was used. Each biphasic shock was delivered after 8 seconds of ventricular fibrillation. A step-up/step-down protocol was used to calculate mean defibrillation threshold before and 10 minutes after coronary artery occlusion using an angioplasty balloon in the left descending artery. At basal state, defibrillation threshold did not differ between the control (20.8 ± 4.8 J), amiodarone (21.2 ± 2 J), and dronedarone (19.5 ± 3 J) groups. After ischemia, the amiodarone group had a significantly higher defibrillation threshold than the control group (29.6 ± 3 J vs. 21.8 ± 5 J, respectively; P = 0.015)...Continue Reading

References

Sep 1, 1989·Journal of the American College of Cardiology·R HernandezM J Reiter
Feb 19, 1987·The New England Journal of Medicine·J W Mason
Jan 15, 1997·The American Journal of Cardiology·K KhalighiM R Gold
Sep 1, 1997·Journal of the American College of Cardiology·V R VorperianC T January
Sep 16, 1998·The American Journal of Cardiology·C Movsowitz, F E Marchlinski
Jan 28, 2003·Journal of Cardiovascular Pharmacology·Patrick GautierDino Nisato
Aug 2, 2003·Journal of Cardiovascular Electrophysiology·Nathalie LalevéeSylvain Richard
Jan 13, 2004·Journal of the American College of Cardiology·Igor SingerJose Brum
Oct 12, 2005·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Dominic A M J TheunsLuc J Jordaens
Oct 28, 2005·Cardiovascular Drug Reviews·Sven KathoferChristoph A Karle
Nov 2, 2005·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Andreas BollmannDavid S Cannom
Jan 13, 2006·JAMA : the Journal of the American Medical Association·Stuart J ConnollyUNKNOWN Optimal Pharmacological Therapy in Cardioverter Defibrillator Patients (OPTIC) Investigators
Sep 20, 2007·JAMA : the Journal of the American Medical Association·Patricia Vassallo, Richard G Trohman
Dec 20, 2007·Journal of Cardiovascular Pharmacology·Philippe ChevalierQuadiri Timour
Jan 22, 2008·Heart & Lung : the Journal of Critical Care·Brian F McBrideJeffery Kluger
Mar 29, 2008·Drugs·Anna Legreid DoppJames E Tisdale
Feb 14, 2009·The New England Journal of Medicine·Stefan H HohnloserUNKNOWN ATHENA Investigators
Sep 1, 2009·European Heart Journal·Harry J G M Crijns
Mar 23, 2010·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Hugo Van HerendaelPaul Dorian
Aug 28, 2010·Pharmacotherapy·Ola O OyetayoPrudence O Hofmann

❮ Previous
Next ❯

Citations

Jun 5, 2016·Cardiac Electrophysiology Clinics·Rafik TadrosJason G Andrade

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.